Close-up on a video camera screen, a woman stares into the lens.

Stay up to date on COVID-19. Learn more

Filter
  • All years
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016

February 22, 2024

Telo Genomics Initiates MRD Clinical Trial for Multiple Myeloma Patients 

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the “Company” or “Telo”) is pleased to announce that it has received the first patient sample for its clinical trial monitoring multiple myeloma (“MM”) disease progression in post-treated patients. The study is being conducted in collaboration with McGill University and the Jewish General[…]

Learn more

February 21, 2024

High BMI in Early Adulthood Increases Multiple Myeloma Risk Among Black Women

High body mass index (BMI) in early adulthood associated with increased risk for multiple myeloma (MM) among Black women, according to results published in the British Journal of Cancer.  The incidence of MM is more than 2-times higher for Black persons. Male gender, age, and African ancestry are established MM risk[…]

Learn more

February 21, 2024

Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial

Due to evolving treatment standards for newly diagnosed multiple myeloma, many patients will be triple-class exposed after initial relapses and have poor survival. Novel therapies and combinations are therefore required to improve outcomes. B cell maturation antigen (BCMA)-targeted biologics have emerged as an important new area of therapeutics for relapsed[…]

Learn more

February 21, 2024

Clinical practice guideline for management of osteoporosis and fracture prevention in Canada: 2023 update

In Canada, more than 2 million people live with osteoporosis, a disease that increases the risk for fractures, which result in excess mortality and morbidity, decreased quality of life and loss of autonomy. This guideline update is intended to assist Canadian health care professionals in the delivery of care to[…]

Learn more

February 21, 2024

International Myeloma Foundation and the Black Swan Research Initiative Showcase Six Oral & Poster Abstracts by the iStopMM Project at the 2023 ASH Annual Meeting

The International Myeloma Foundation’s Black Swan Research Initiative® (BSRI) proudly showcased four oral and two poster abstracts from the iStopMM (Iceland Screens, Treats, or Prevents Multiple Myeloma) Project during the 65th American Society of Hematology (ASH) Annual Meeting in San Diego, CA which took place from December 9-12, 2023.    Read more…  […]

Learn more

February 21, 2024

Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for ASCT: Primary Results of the Perseus Trial

Pieter Sonneveld, MD, PhD (Erasmus MC Cancer Institute — Rotterdam, Netherlands) discusses the effectiveness of Daratumumab (DARA SC) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as induction/consolidation therapy as opposed to VRd alone in myeloma patients eligible for autologous stem cell transplantation.  Watch the video now…  […]

Learn more
1 2 3 10

Myeloma Canada updates

 

Filter
  • All years
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016

February 22, 2024

IMAGINE CANADA Organization Spotlight: Myeloma Canada 

Established in 2005, Myeloma Canada is the only national charitable organization created by, and for, Canadians impacted by multiple myeloma. Their mission is to improve the lives of those affected by this disease by empowering our community through awareness, education, and advocacy programs, and by supporting clinical research to find[…]

Learn more

February 20, 2024

2023 Dr Andrew R Belch MEET Grant for young myeloma investigators 

A total of 8 MEET Grants were awarded in 2023. Click on the links below to view video presentations from select winners and their important work.  Dory Abelman: Cell-Free DNA from Blood or Bone Marrow as Alternatives to Bone Marrow Cells for Molecular Diagnostics and Monitoring of Multiple Myeloma  “I am profoundly[…]

Learn more

February 4, 2024

A new multiple myeloma trial assessing the duration of treatment injections has opened in Canada.

The CCTG MY13 trial is a phase III non-inferiority randomized controlled trial of fixed duration versus continuous daratumumab among transplant in eligible older adults with newly diagnosed multiple myeloma. There is little scientific evidence around the effective timing of injectable treatments for multiple myeloma. These patients receive treatment with three medicines[…]

Learn more

December 15, 2023

Opinion: CAR T-Cell THERAcell therapy delays jeopardize lives of Canadians with blood cancer

Myeloma Canada is a member of thecancercollaborative (Colab) a cancer collaborative and patient-driven think-tank dedicated to bridging science, policy, and advocacy to accelerate policy change and make a meaningful contribution to cancer care. Along with other members, we signed Colab’s opinion letter for a multi-stakeholder approach to develop solutions that[…]

Learn more

October 24, 2023

UCalgary and AHS researchers discover how multiple myeloma cells become resistant to immunotherapy

Lisa Mack is cancer free, for now, and looking forward to her 75th birthday in December. She was a participant in a clinical trial at the Tom Baker Cancer Centre (TBCC) that has helped University of Calgary and Alberta Health Services researchers better understand why multiple myeloma (MM) cells become[…]

Learn more

October 20, 2023

Ontario, Nova Scotia and British Columbia, rejoice! Selinexor is now funded in your province!

We are thrilled to inform you that, effective September 7th, XPOVIO® (selinexor) in combination with bortezomib and dexamethasone (XVd) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy, is now funded in Ontario, since September 7, as wells as in Nova Scotia[…]

Learn more
1 2 3 16